Cover Image

Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC

Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients,...

Full description

Saved in:
Bibliographic Details
Main Authors: Sahin, Ugur (Author) , Schmidt, M. (Author) , Derhovanessian, E. (Author) , Cortini, A. (Author) , Vogler, I. (Author) , Omokoko, T. (Author) , Godehardt, E. (Author) , Attig, S. (Author) , Newrzela, S. (Author) , Grützner, J. (Author) , Bidmon, N. (Author) , Bolte, S. (Author) , Brachtendorf, S. (Author) , Stuhlmann, T. (Author) , Langer, D. (Author) , Brüne, D. (Author) , Blake, J. (Author) , Feldner, A. (Author) , Lindman, H. (Author) , Schneeweiss, Andreas (Author) , Eichbaum, M. (Author) , Türeci, Ö (Author)
Format: Article (Journal)
Language:English
Published: 26 March 2026
In: Nature
Year: 2026, Volume: 651, Issue: 8107, Pages: 1088-1096, [1-22]
ISSN:1476-4687
DOI:10.1038/s41586-025-10004-2
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41586-025-10004-2
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41586-025-10004-2
Get full text
Author Notes:U. Sahin, M. Schmidt, E. Derhovanessian, A. Cortini, I. Vogler, T. Omokoko, E. Godehardt, S. Attig, S. Newrzela, J. Grützner, N. Bidmon, S. Bolte, S. Brachtendorf, T. Stuhlmann, D. Langer, D. Brüne, J. Blake, A. Feldner, H. Lindman, A. Schneeweiss, M. Eichbaum & Ö Türeci
Description
Summary:Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of ‘ready-to-act’ cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches.
Item Description:Online veröffentlicht: 18. Februar 2026
Gesehen am 10.04.2026
Physical Description:Online Resource
ISSN:1476-4687
DOI:10.1038/s41586-025-10004-2

Similar Items